List view / Grid view
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
The identification and validation of novel drug targets is a challenging process for drug discovery programmes.
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.
Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount of time in order to work efficiently.
Two studies reveal the importance of timing in Huntington’s disease interventions and demonstrate interleukin-6 may play a protective role.
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Learn practical tips from eight Principal Investigators about how to start your own lab.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
